Neu-REFIX Beta Glucan Receives Rare Pediatric Disease and Orphan Drug Designations from the US FDA for Treatment of Duchenne Muscular Dystrophy

Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation and Orphan Drug Designation from the US FDA for the treatment of Duchenne muscular Dystrophy. These designations would help take the progress in pre-clinical and clinical studies conducted in Japan and India to clinical trials in the USA, for approval by FDA.